Phillips Law Group Reports GLP-1 Injury Claims

The Phoenix firm says it represents about 20 clients alleging digestive and vision-related harm from GLP-1 weight-loss medications.

Updated on Nov. 4, 2026 in Weight Loss

Phillips Law Group Reports GLP-1 Injury Claims

Live Poll

Would you take a GLP-1 medication despite its possible side effects?

Phillips Law Group, with an uptown Phoenix location, represents approximately 20 clients with claims tied to GLP-1 medications such as Ozempic, Wegovy, Mounjaro, Zepbound and Rybelsus. The firm currently has two litigations, one covering gastrointestinal issues and one covering non-arteritic anterior ischemic optic neuropathy (NAION).

Why it matters

Lawyers say manufacturers may not have adequately warned patients about the risk of severe digestive complications. Studies suggest a possible connection between semaglutides and increased NAION risk, though data is not sufficient to recommend patients stop taking their medications.

The figures come from a single firm's caseload of about 20 clients across two litigations, not from a controlled study or regulatory filing. Whether these claims will be substantiated has not been determined.

The players

Phillips Law Group

A law firm representing about 20 clients with GLP-1 medication injury claims and two active litigations.

The details

Phillips Law Group says the most common GLP-1 side effects are gastrointestinal, including worsened acid reflux, and that symptoms are often most noticeable during the first 24 to 48 hours after an injection. Many GI effects may be managed through hydration, fiber intake, minimally processed foods and limiting greasy or high-fat meals.

Symptoms are often most noticeable during the first 24 to 48 hours after an injection.
In March, the American Academy of Ophthalmology Journal published NAION studies on semaglutides.

Health Landscape

Concerns about semaglutide-related NAION risk have emerged through peer-reviewed ophthalmology research rather than regulatory action alone. The current litigation reflects how individual claims are developing alongside that published evidence.

Patients on GLP-1 medications may experience acid reflux or digestive symptoms that are often most noticeable in the first 24 to 48 hours after injection. Hydration, fiber intake and limiting greasy or high-fat meals may help manage these effects.

The takeaway

Patients on GLP-1 medications should discuss digestive and vision-related symptoms with their prescribing clinician. The current data does not support stopping treatment based on NAION risk alone.